Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.45 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.45 |
| ▸ | PLAU | P00749 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MC4R | P32245 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | MC3R | P41968 | 1/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.42 |
| ▸ | GABRP | O00591 | 1/20 | 0.41 |
| ▸ | GABRD | O14764 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2328151 | 1.00 | RECQL (0.50) | RECQLCYP4F2CYP4A11PLAUADORA3 | |
| SCHEMBL2176535 | 0.85 | LOXL2 (0.56) | CYP4F2CYP4A11ADORA3TSHRMC4R | |
| SCHEMBL20377228 | 0.85 | CYP4F2 (0.45) | CYP4F2CYP4A11ADORA3TSHRMC4R | |
| SCHEMBL1388918 | 0.84 | GRM2 (0.46) | CYP4F2CYP4A11ADORA3TSHRMC4R | |
| Hydrochloric Acid SCHEMBL5013437 | 0.83 | LOXL2 (0.55) | CYP4F2CYP4A11ADORA3TSHRMC4R | |
| SCHEMBL2642856 | 0.83 | CYP4F2 (0.44) | CYP4F2CYP4A11ADORA3TSHRMC4R | |
| SCHEMBL2677778 | 0.83 | SMYD3 (0.54) | CYP4F2CYP4A11ADORA3TSHRMC4R | |
| SCHEMBL19211551 | 0.83 | CYP4F2 (0.44) | RECQLCYP4F2CYP4A11ADORA3TSHR | |
| SCHEMBL4016509 | 0.83 | CYP4F2 (0.44) | CYP4F2CYP4A11ADORA3TSHRMC4R | |
| SCHEMBL4302305 | 0.83 | CYP4F2 (0.43) | RECQLCYP4F2CYP4A11PLAULOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263399-A1 | CBL-B MODULATORS AND USES THEREOF | SCHRÖDINGER, INC. | 2025-08-21 | — | — | US | disclosed |
| US-11931348-B2 | Methods of treating elevated plasma cholesterol | Montréal Heart Institute (CA) | 2024-03-19 | — | — | US | disclosed |
| CN-112638477-B | Pyrrolo [2,3-B ] pyridine derivatives as inhibitors of influenza virus replication | 共晶制药公司 | 2024-01-26 | — | — | CN | disclosed |
| US-20230088095-A1 | METHODS OF TREATING ELEVATED PLASMA CHOLESTEROL | Montréal Heart Institute (CA) | 2023-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250263399-A1 | CBL-B MODULATORS AND USES THEREOF | CBLB, CBL, CBLC | RECQL 2302/4885CYP4F2 3529/4885CYP4A11 3921/4885 |
| US-11931348-B2 | Methods of treating elevated plasma cholesterol | CETP, LDLR, APOB | RECQL 2203/4885CYP4F2 171/4885CYP4A11 76/4885 |
| US-20230088095-A1 | METHODS OF TREATING ELEVATED PLASMA CHOLESTEROL | CETP, LDLR, APOB | RECQL 2203/4885CYP4F2 171/4885CYP4A11 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.